Gazella's Newest Health Book Documents Wide-Reaching Health Benefits of Modified Citrus Pectin

June 4
10:23 2014
Gazella's Newest Health Book Documents Wide-Reaching Health Benefits of Modified Citrus Pectin

SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ One of the nation's leading writers on the use of naturopathic medicine has released a new book documenting groundbreaking studies on modified citrus pectin (MCP) and its application for addressing serious health issues like cancer, heart disease, chronic inflammation and fibrosis.

The book, New Twist on Health: Modified Citrus Pectin for Cancer, Heart Disease and More by Karolyn A. Gazella, centers on the integrative medical breakthroughs brought about through the study of MCP. A commonly used nutraceutical ingredient, MCP is a specialized form of citrus pectin that is modified for enhanced absorption and therapeutic benefit. MCP has been the subject of numerous preclinical and clinical studies and is currently being investigated as a treatment for serious medical conditions including congestive heart failure, fibrosis, cancer metastasis, cirrhosis, asthma and more. It has also been clinically proven to gently remove heavy metals and environmental toxins from the body without affecting essential minerals.

"MCP could have a wide range of applications to help patients and medical professionals address some of society's most pressing health challenges, and I am thrilled to release a book detailing this important work," said Gazella. "The discovery and development of MCP is a subject on which every medical practitioner should be informed. This book provides the essential background and insight into the formation of what could potentially be one of the most important integrative medical breakthroughs of the century."

New Twist on Health describes the way in which MCP has been shown to inhibit the inflammatory protein galectin-3, which is associated with cancer progression and metastasis, congestive heart failure, chronic inflammation and fibrosis, as well as a variety of other medical conditions. MCP absorbs into the bloodstream, binding to excess galectin-3 and blocking this "rogue protein" from being expressed. The book specifically analyzes the research behind PectaSol-C , currently the only clinically proven brand of MCP on the market.


Become a Fan, Follower & Subscriber

           Facebook Like Follow